StonvexLoading…
StonvexStonvexStonvexCore line items from DKS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2026 2026-01-31 | Q4 2025 2025-11-01 | Q3 2025 2025-08-02 | Q2 2025 2025-05-03 |
|---|---|---|---|---|
Revenue | $17.22B | $10.99B | $6.82B | $3.17B |
Operating Income | $1.10B | $911.40M | $818.30M | $366.12M |
Net Income | $849.24M | $720.90M | $381.40M | $264.29M |
EPS (Diluted) | $9.97 | $8.66 | $7.95 | $3.24 |
Total Assets | $17.41B | $17.43B | $10.69B | $10.43B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $1.35B | $821.33M | $1.23B | $1.04B |
Free Cash Flow OCF − CapEx | $400.17M | $-306.03M | $209.56M | $-86.68M |
Shares Outstanding | 85.14M | 83.21M | 81.26M | 81.48M |